Delivery Order SPE2DB20D3111-SPE2DB25FA7MQ
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $41,236.32 for the supply of Ondansetron HCL 4 mg tablets (500-count units) with a completion date of November 17, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating it was competitively awarded through open competition. Performance will be executed at AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,537.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count) with an ultimate completion date of October 22, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $8,258.16 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be completed by August 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,030.04 to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Ondansetron HCL 4 mg tablets (500-count units). This is a firm fixed-price delivery order with no set-aside designation, completed competitively through open procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of April 22, 2025. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $4,077.93 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-unit quantity) with a completion date of December 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) under a firm fixed-price contract valued at $23,344.88. The contract was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability...
- The Defense Logistics Agency awarded a delivery order valued at $11,752.69 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units) with an ultimate completion date of June 2, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a competitive award under the company's larger pharmaceutical supply agreement with DLA. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,923.09 to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and carries an ultimate completion date of June 27, 2025. Performance will be executed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count packaging) with a ceiling value of $1,325.40. This competitively awarded, firm fixed-price delivery order was issued on November 17, 2025, with an ultimate completion date of November 18, 2025. The contract carries no set-aside designation, and performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,110.41 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on August 14, 2025, with ultimate completion scheduled for August 15, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform this work at its corporate...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA7MQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,856.54 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count units). The contract is a firm fixed price delivery order with no set-aside designation, competitively awarded on April 24, 2025, with an ultimate completion date of April 25, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime IDV serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs globally. The underlying contract supports multiple federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard, as part of DLA's pharmaceutical procurement strategy for federal medical supply needs across the defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 4/24/25 |